



METHOD OR KIT FOR DETERMINING LUNG CANCER

(Below is limited to 1-page only; be careful not to disclose vital technology content. Please delete these words when the document is finished)

PI : Prof. Sung-Liang Yu

Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan U.

Experience:

Department of Clinical Laboratory Sciences and Medical Biotechnology, NTUCM

Graduate Institute of Clinical Medicine, NTUCM

Graduate Institute of Pathology, NTUCM

Institute of Medical Device and Imaging, NTUCM

Center for Optoelectronic Biomedicine and Center for Genomics Medicine, NTUCM

Market Needs:

1. Cancer prevention
2. Screening for high risk population in lung cancer

Our Technology:

Disclosed herein is a method of determining whether a subject having or is at risk of developing lung cancer. The presence of the SNP locus of rs193100333, which corresponds to a mutation on YAP1 protein with a substitution of an arginine to a tryptophan at position 331, indicates the subject has or is at risk of developing lung cancer. Accordingly, also disclosed herein is a kit for facilitating the detection of the SNP locus of rs193100333.

Strength:

Current methods for risk evaluation of lung cancer are lack of precision effectiveness. A method present here has high accuracy and validity.

Competing Products:

Non

Intellectual Properties:

1. Taiwan patent No. I607091
2. US patent application No. 15/272,442

Contact (do not need to fill out):

Center for Industry-Academia Cooperation, NTU
Tel: 02-3366-9945, E-mail: ntuciac@ntu.edu.tw